Announcements Trials
Browse Landscape

Phase

Phase 1 19Phase 1/2 5Phase NA 1

Status

Unknown 3Recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Carcinoma, Non-Small-Cell Lung 438Neoplasms 363Breast Neoplasms 261Colorectal Neoplasms 244Neoplasm Metastasis 216Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 182Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 125Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 97Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

Clinical Trials, Phase II as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Advanced Malignant Solid Tumors × Clear all
NCT06499350 2026-03-10

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

FindCure Biosciences (ZhongShan) Co., Ltd.

Phase 1/2 Recruiting
33 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT06464055 2025-02-10

A Study of GQ1010 in Subjects With Advanced Solid Tumors

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Phase 1/2 Recruiting
260 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT05338957 2022-12-01

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Shanghai Miracogen Inc.

Phase 1/2 Unknown
30 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT05478785 2022-07-29

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Unknown
126 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT04226066 2020-12-07

Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Tasly Tianjin Biopharmaceutical Co., Ltd.

Phase 1/2 Unknown
69 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡